Ergoteles’s Monte Rosa Therapeutics GLUE Stock Holding History

Ergoteles’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-74,510	Closed	-$1.52M	–	1374
2021 Q4	$1.52M	Buy	+74,510	New	+$1.56M	0.06%	318

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Ergoteles's GLUE Position: Q1 2022 in Review

Ergoteles sold out of Monte Rosa Therapeutics (GLUE) in Q1 2022, closing a stake of 74,510 shares — an estimated $1.52M sold.

Ergoteles first reported a position in GLUE in Q4 2021 and held it in 1 quarter. The position peaked at $1.52M in Q4 2021. 52 funds tracked by Wall St. Rank hold GLUE as of Q1 2022.

Ergoteles reported no remaining Monte Rosa Therapeutics position as of Q1 2022 after selling out during the quarter.
Ergoteles sold 74,510 Monte Rosa Therapeutics shares in Q1 2022, an estimated $1.52M.
Ergoteles first reported a position in Monte Rosa Therapeutics in Q4 2021 and held it in 1 quarter.
Ergoteles's Monte Rosa Therapeutics position peaked at $1.52M in Q4 2021.
52 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.